To apply Susavion’s MultiValent Peptide Mimetic (MVPM) Technology platform to develop drugs that harness the power of the immune system to combat cancer
and other major diseases.
Susavion Biosciences, Inc., a privately-owned company formed to advance technology based on multi-valent, bio-active peptides suitable for use as therapeutic modulators of the immune system.
- Incorporated in 2006
- 10 issued patents, 6 pending
- Therapeutic efficacy demonstrated
Laura L. Eggink, PhD, President
A former Assistant Professor Research of Biomedicine and Biotechnology at Arizona State University is a leading researcher on peptide mimetics.
Also an expert on cell signaling, she has worked with a number of experimental models ranging from chloroplasts to macrophages. Dr. Eggink, the inventor on 11 patents and 6 applications, is a leading investigator demonstrating the feasibility of modulating the immune system with peptide mimetics of carbohydrates.
Kenneth Hoober, PhD, Chief Scientific Officer
As the Chair of Biochemistry, Temple Univ. School of Medicine and most recently, Chair in the School of Life Sciences, Arizona State University, Dr. Hoober has contributed to over 100 research publications.
Dr. Hoober has devoted much of his career to understanding mechanisms of membrane biogenesis. He is particularly known for his contributions to the field of chloroplast membrane protein chemistry and synthesis. Dr. Hoober was involved in the early work on GcMAF and its ability to stimulate the activation of macrophages.
David McCaleb, MBA
He started his year career at Merck with the launch of enalapril, then continued bringing blockbuster products to the pharmaceutical and biotech markets, launching several billion dollar products. Established commercial operations at Amgen, Cephalon, Gilead and CV Therapeutics. Led a number of creative partnering deals, including Amgen-Roche and CVT-Quintiles. Mr. McCaleb has participated in raising over a billion dollars in capital.